Virtual Library
Start Your Search
K. Chen
Author of
-
+
P2.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 210)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.02-025 - The Equivalent Efficacy of Multiple Operations for MPLC and a Single Operation for SPLC (ID 253)
09:30 - 09:30 | Author(s): K. Chen
- Abstract
Background:
The incidence of synchronous and metachronous multiple primary lung cancers (MPLCs) has been increasing recently. The new multidisciplinary classification of lung adenocarcinoma and TNM Classification of Lung Cancer (7[th] edition, 2009), have improved the understanding of MPLC. Most researchers recommend that surgical therapy be actively pursued if the patient’s physical condition and lung function permit it and if a complete cure can be achieved. However, few studies have reported the long-term efficacy of surgical treatment for MPLC, which we explored in this study.
Methods:
One thousand two houndred and ningty Lung cancer patients from a prospectively maintained database, treated by a single surgeon group between January 2000 and July 2013, at Beijing Cancer Hospital, Peking University, were reviewed. We retrospectively analyzed the clinical data of 31 patients diagnosed with MPLC out of 1290 lung cancer patients, focusing on long-term survival.
Results:
MPLC patients accounted for 2.4% (31/1290) of the patient cohort: 27 had synchronous MPLC (87.1%) and 4 had metachronous MPLC (12.9%). The 1- and 3-year postoperative survival rates were 100% and 73.5%, respectively. On stratification according to TNM stage, the 1- and 3-year survival rates of patients with stage I cancer (20 patients) were 100% and 77.8%, respectively, not statistically significant with those for the entire cohort (1290 patients; 95.4% and 80.5%, respectively, p=0.876).
Conclusion:
When the patient’s physical condition and tumor-related factors permit it, surgery should be the first choice of treatment for MPLC; it is associated with an equivalent efficacy to that of surgery for single primary lung cancer.